SBIR/STTR Research Award
AN EASY-TO-USE, LOW-COST TRIPLEX RDT FOR THE SIMULTANEOUS DIAGNOSIS OF HBV, HCV, AND HIV INFECTION, COMPATIBLE WITH FIELD USE IN LMICS AND AT-HOME USE IN THE US
Award amount
$299,659Program and phase
SBIR · Phase IAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIG EYE DIAGNOSTICS INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- C3KTPAW1E1Z7
- Solicitation number
- PHS-2024-1
- Topic code
- 127
Research abstract
Multiplexed Patient Administered Diagnostics for Hepatitis B, Hepatitis C, and HIV: HIV and viral hepatitis infections share common modes of transmission and social and structural barriers to accessing care and services among key populations. Coinfection with HIV significantly impacts the pathogenesis of HBV and HCV and is associated with reduced spontaneous clearance of HCV and HBsAg, higher rates of chronicity and occult HBV, higher HCV viral loads, rapid disease progression, and increased risk of morbidity and mortality due to cirrhosis and HCC. Integrated strategies for screening and diagnosis of HIV and viral hepatitis infections are therefore critical to an effective global health response. This contract aims to to develop mono-plex prototypes of a patient administered diagnostic test for HBV, HCV, and HIV using antibody detection in a lateral flow assay.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- An Antigen-Based Rapid Test to detect L. loa infections, Aimed at Supporting Onchocerciasis Elimination Programs
- Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis
- Supporting WHO Lymphatic Filariasis Elimination Programs: Progressing a Highly Sensitive and Specific Rapid Diagnostic Test for Brugia Species Infection to Commercialization Readiness
- SUPPORTING WHO ONCHOCERCIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND ULTRA-SPECIFIC RAPID DIAGNOSTIC TEST TO COMMERCIALIZATION READINESS
- First-in-class, highly sensitive and specific rapid diagnostic test to detect Paragonimus infections
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A SIMPLE MULTIPLEXED PLATFORM FOR SELF-ADMINISTERED HIV AND HEPATITIS B TESTING
- DEVELOPMENT OF AN ULTRASENSITIVE, RAPID AND EASY-TO USE AT-HOME MOLECULAR TEST FOR HCV, HBV AND HIV
Research funding history
7 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $5,835,895. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services